Middle East & Africa Coagulation Market Forecast to 2030 - Regional Analysis - by Disease Indications, Type, Technology, and End User

The Middle East & Africa coagulation market was valued at US$ 291.47 million in 2022 and is expected to reach US$ 467.78 million by 2030; it is estimated to grow at a CAGR of 6.1% from 2022 to 2030.

Development of Point-of-Care (POC) Coagulation Analyzers Fuel Middle East & Africa Coagulation Market

A rapid, reliable assessment of hemostasis is essential for patients suffering from trauma or other bleeding problems. Due to the constraints of sample preparation and analytical process, routine coagulation assays cannot analyze clot formation, and their results can be obtained only after 30-90 minutes. POC devices such as platelet function test, viscoelastic coagulation tests, blood gas analysis, and other coagulometers are available for assessment of hemostasis. A POC measurement tool can be used inside and outside the hospital as a decision-making and management tool. When time is paramount, POC analyzers provide immediate, actionable results in emergency rooms, coronary care units, surgery, and procedure suites. In addition to outpatient clinics and physicians' offices, these devices can assist in patient management in pharmacies, care centers, and patients' homes. POC coagulation analyzers offer timely results without compromising diagnostic quality control provided by central labs. In POC testing, it is important to provide fast results, along with accuracy and quality assurance.

In 2021, Siemens Healthineers launched fully automated CN-3000 and CN-6000 systems, which are mid- and high-volume handheld POC coagulation testing devices. The FDA cleared Siemens Healthineers' Xprecia Stride Coagulation Analyser in 2016, as a POC coagulation analyzer device. The device has demonstrated prothrombin time/international normalized ratio (PT/INR) testing performance equivalence to Roche CoaguChek XS.

Thus, the growing developments in POC coagulation analyzers are expected to boost the coagulation market growth during the forecast period.

Middle East & Africa Coagulation Market Overview

The Middle East & Africa coagulation market has been segmented into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. Market growth in this region is mainly ascribed to developments in medical facilities, the increasing prevalence of blood disorders, and the growing incidence of AFib and other cardiovascular diseases.

Saudi Arabia is one of the important Middle Eastern countries with significant scope for the coagulation market. According to the "Assessment of Venous Thromboembolism Awareness in Makkah, Saudi Arabia" study, venous thromboembolism affects ~25,000 people in Saudi Arabia every year. As per the article "Prevalence of venous thromboembolism in patients with acetabular or hip fractures," published in the Journal of Musculoskeletal Surgery and Research in 2020, the prevalence of hospital-acquired deep vein thrombosis in Saudi Arabia ranges from 10% to 40% in surgical and medical patients. Venous thromboembolism and deep vein thrombosis is a condition where blood clot occurs in the body part such as the deep vein. Thus, the increasing prevalence of blood disorders such as venous thromboembolism, hemophilia, and clotting factor diseases is fueling the growth of the market in Saudi Arabia.

Middle East & Africa Coagulation Market Segmentation

The Middle East & Africa coagulation market is segmented based on disease indication, type, offering, technology, end user, and country.

Based on disease indication, the Middle East & Africa coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand's disease, and others. The liver disease segment held the largest Middle East & Africa coagulation market share in 2022.

Based on type, the Middle East & Africa coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held a larger Middle East & Africa coagulation market share in 2022. Clinical laboratory analysers segment is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.

In terms of offering, the Middle East & Africa coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held a larger Middle East & Africa coagulation market share in 2022. Diagnosis segment is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment segment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.

By technology, the Middle East & Africa coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held the largest Middle East & Africa coagulation market share in 2022.

By end user, the Middle East & Africa coagulation market is segmented into clinical laboratories, hospitals, and others. The hospitals segment held the largest Middle East & Africa coagulation market share in 2022.

Based on country, the Middle East & Africa coagulation market is categorized into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa coagulation market in 2022.

Siemens Healthineers AG; ImproGen Diagnostik Kimya San & Tic Ltd ?ti; Sysmex Corp; F. Hoffmann-La Roche Ltd; Genrui Biotech Co Ltd; Transasia Bio-Medicals Ltd; and Horiba Ltd are some of the leading companies operating in the Middle East & Africa coagulation market.